We are excited to announce that Peyton Greenside, BigHat’s Co-founder and CSO will be participating in the Timmerman Traverse for Sickle Forward, an inspiring expedition to the summit of Mt. Kilimanjaro (19,340 ft / 5,895 m) from September 8-17, 2024. This journey, led by Luke Timmerman, founder/editor of the Timmerman Report, Dr. Ted Love, former President and CEO of Global Blood Therapeutics, and Dr. Alan Anderson, Lifespan Hematologist and Global Sickle Cell Disease Clinician, aims to raise funds for the diagnosis and treatment of sickle cell disease (SCD) in sub-Saharan Africa.
About the Challenge
Peyton, along with patient advocates and other leaders in the SCD community, will come together under the mission to raise at least $50,000 each, contributing to a collective goal of $1 million for Sickle Forward. The funds raised will be matched directly, effectively doubling the impact of this initiative.
The Importance of SCD Awareness and Treatment
SCD is the most common inherited blood disorder, affecting over 6 million people worldwide, with the highest prevalence in sub-Saharan Africa. Tragically, many children born with SCD in this region go undiagnosed and untreated, leading to high mortality rates. An estimated 300,000 children are born with SCD in sub-Saharan Africa each year, and 50-80% of these children die before the age of 5 due to lack of diagnosis and basic treatment.
Sickle Forward envisions a future where all newborns, regardless of where they are born, have access to diagnosis and treatment. Funds raised from the Timmerman Traverse will support the expansion of newborn screening and provide access to life-saving treatments such as antibiotic prophylaxis, malaria prevention, basic immunizations, and hydroxyurea.
Join Us in Making a Difference
We invite you to support Peyton and the entire Timmerman Traverse team in their cause. Your contributions will help fund systematic newborn screening and treatment programs in sub-Saharan Africa, saving countless lives and giving children the chance for a healthier future. Stay tuned for updates on Peyton's journey and our fundraising progress. Together, we can make a significant impact on the fight against Sickle Cell Disease.
For more information and to support, please visit: https://givebutter.com/TimmermanTraverseforSickleForward/peytongreenside
BigHat's SCD Program
To address the unmet need of patients with SCD, BigHat has designed a next-generation antibody now in preclinical development to treat and prevent SCD vaso-occlusive crises. Reach out to partnering@bighatbio.com to learn more.
